Key Points
- EVP Sandra Van Der Vaart sold 548 shares for $156,130.68, reducing her stake by 17.52% to 2,579 shares (SEC Form 4 disclosure).
- Labcorp beat quarterly EPS expectations with $4.07 EPS vs. $3.95 expected while revenue was $3.52B (slightly below the $3.56B estimate); revenue rose 5.6% year-over-year and the company set FY2026 guidance of $17.55–$18.25 EPS, with analysts holding a consensus "Moderate Buy" and an average target of $304.82.
- Quarterly dividend of $0.72 per share was declared (annualized $2.88), with ex-dividend and record date on Feb 27 and payment scheduled for Mar 12, implying a ~1.0% yield.
Labcorp Holdings Inc. (NYSE:LH - Get Free Report) EVP Der Vaart Sandra Van sold 548 shares of the firm's stock in a transaction dated Friday, February 27th. The shares were sold at an average price of $284.91, for a total value of $156,130.68. Following the transaction, the executive vice president directly owned 2,579 shares in the company, valued at $734,782.89. This trade represents a 17.52% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website.
Labcorp Trading Down 1.2%
NYSE LH opened at $283.15 on Wednesday. The firm has a market cap of $23.33 billion, a PE ratio of 27.07, a price-to-earnings-growth ratio of 1.96 and a beta of 1.01. Labcorp Holdings Inc. has a 1-year low of $209.38 and a 1-year high of $293.72. The stock has a 50-day moving average of $269.72 and a 200-day moving average of $270.19. The company has a current ratio of 1.42, a quick ratio of 1.23 and a debt-to-equity ratio of 0.60.
Labcorp (NYSE:LH - Get Free Report) last posted its quarterly earnings results on Tuesday, February 17th. The medical research company reported $4.07 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.95 by $0.12. Labcorp had a return on equity of 16.16% and a net margin of 6.28%.The business had revenue of $3.52 billion for the quarter, compared to analyst estimates of $3.56 billion. During the same period last year, the company earned $3.45 EPS. Labcorp's revenue for the quarter was up 5.6% compared to the same quarter last year. Labcorp has set its FY 2026 guidance at 17.550-18.250 EPS. As a group, sell-side analysts forecast that Labcorp Holdings Inc. will post 16.01 EPS for the current year.
Labcorp Dividend Announcement
The company also recently disclosed a quarterly dividend, which will be paid on Thursday, March 12th. Stockholders of record on Friday, February 27th will be paid a dividend of $0.72 per share. This represents a $2.88 annualized dividend and a dividend yield of 1.0%. The ex-dividend date of this dividend is Friday, February 27th. Labcorp's dividend payout ratio is 27.53%.
Wall Street Analysts Forecast Growth
A number of research analysts have commented on LH shares. Morgan Stanley reaffirmed an "overweight" rating on shares of Labcorp in a research report on Tuesday, February 17th. Robert W. Baird raised their price target on Labcorp from $313.00 to $326.00 and gave the stock an "outperform" rating in a research note on Wednesday, February 18th. Piper Sandler boosted their price objective on shares of Labcorp from $270.00 to $300.00 and gave the company a "neutral" rating in a research report on Tuesday, February 24th. JPMorgan Chase & Co. raised their target price on Labcorp from $319.00 to $330.00 and gave the company an "overweight" rating in a research note on Wednesday, February 18th. Finally, Weiss Ratings upgraded shares of Labcorp from a "hold (c+)" rating to a "buy (b-)" rating in a report on Tuesday, February 10th. Nine research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $304.82.
Get Our Latest Research Report on LH
Institutional Investors Weigh In On Labcorp
Large investors have recently bought and sold shares of the business. Caldwell Trust Co purchased a new position in Labcorp in the 2nd quarter worth about $25,000. JPL Wealth Management LLC bought a new stake in shares of Labcorp in the third quarter worth $28,000. Financial Gravity Companies Inc. purchased a new stake in Labcorp during the second quarter valued at $26,000. Thurston Springer Miller Herd & Titak Inc. bought a new position in Labcorp in the fourth quarter valued at about $26,000. Finally, Hilton Head Capital Partners LLC bought a new position in Labcorp in the fourth quarter valued at about $27,000. 95.94% of the stock is currently owned by institutional investors.
Labcorp Company Profile
(
Get Free Report)
Laboratory Corporation of America Holdings, commonly known as Labcorp (NYSE: LH), is a global life sciences company that provides comprehensive clinical laboratory and drug development services. The company operates a broad network of laboratories, patient service centers and specialty testing sites to deliver diagnostic information and testing solutions that support patient care, clinical decision-making and population health initiatives.
Labcorp's core businesses encompass clinical laboratory testing and pharmaceutical development services.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
